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Objectives: To understand why dronedarone failed to unseat amiodarone as the 
primary antiarrhythmic treatment of choice for persistent AF, thus uncovering the 
clinical outcome requirements for a future AF therapy to achieve optimal market 
access. MethOds: Review published HTA reports and clinical trial outcomes for 
dronedarone to assess market access outcomes and associated Payer rationale for 
decision-making. Interview ten (10) managed care medical directors and AF key 
opinion leaders (KOLs) in US and thirteen (13) ex-Payers and AF KOLs in Europe 
(mix of stakeholders encompassing France, Germany, Italy, Spain, and UK) for vali-
dation and gap filling. Results: Driven by benefits in all efficacy outcomes other 
than cardiovascular-related hospitalizations, Payers perceive amiodarone as more 
efficacious than dronedarone. The significant number of deaths during the high-
risk PALLAS study crippled the safety image of dronedarone. Finally, a prohibitive 
price at launch contributed to a multiplicity of negative HTA assessments. In order 
to succeed where dronedarone failed and qualify as a step function increase over 
the standard-of-care amiodarone, Payers require at least: 40% reduction in AF recur-
rence; 30% relative risk reduction in hospitalizations compared to amiodarone; 
and fewer than 1% deaths as part of the clinical evidence package. Lower rates of 
bradyarrhythmia, liver toxicity, and no proarrhythmia will drive a favorable regula-
tory safety evaluation compared to amiodarone. cOnclusiOns: The sub-optimal 
market access and relatively low utilization of dronedarone resulted primarily from 
a failure to demonstrate an improvement in recurrence as compared to amiodar-
one, as well as a significant number of deaths during pivotal trials. Manufacturers 
considering development of novel antiarrhythmics should strive for equivalent 
efficacy but superior safety to amiodarone if a 40% reduction in recurrence is not 
clinically feasible.
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Objectives: Existing heart failure standard of care (SoC) provides symptom 
relief with no impact on changing the disease course. This research assessed 
Payers’ perceived value and willingness to pay (WTP) for a novel oral therapy 
with significant improvement on top of SoC and a cell therapy providing poten-
tial disease modifying outcomes and enhanced mortality benefit. MethOds: An 
online survey with 22 US and EU-5 Payers assessing perceptions of current SoC 
therapies was conducted. A systematic evaluation of heart failure pharmaceuti-
cal, biologic and cell based therapies under clinical development was performed 
from which two hypothetical product profiles were developed: 1) a novel orally 
administered therapy; and 2) a recombinant cell based treatment via intramyo-
cardial infusion. Profiles were then tested by 30 in-depth interviews with US and 
EU-5 Payers. Results: Payer preference is based on the technology’s ability to 
meet efficacy targets treating the broadest heart failure patient segments. The 
oral agent was the preferred agent due to the clinical feasibility to develop with a 
WTP per day of US $8, UK £ 3 and EU € 5 based on efficacy: ≥ 28% RRR composite 
of CV death and HF hospitalizations; ≥ 25% RRR in CV mortality and ≥ 25% RRR 
in all-cause mortality. The cell based therapy was cited as the most promising 
by improving symptoms and changing disease course with a WTP per treatment 
of US $6,500, UK £1,200 and EU € 1,000 based on efficacy: improvement of NYHA 
functional class in ≥ 15% of patients in 1 year and ≥ 15% improvement in heart 
function. cOnclusiOns: Payers see novel oral therapies as highly feasible and 
efficient in treating the broadest population and are willing to pay a premium. 
However, technologies that are disease modifying, reduce hospitalizations, and 
provide a significant mortality benefit are most desirable notwithstanding the 
considerable cost of treatment.
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Objectives: Chest pain complaint is a common and difficult condition to diagnose 
due to the diversity of the underlying conditions that could cause it. The objective 
of this study is to examine the impact of the uncertainty in diagnosis on resource 
utilization using chest pain as an example. MethOds: Cross-sectional explora-
tion of the National Hospital Ambulatory Medical Care Survey (NHAMCS) for U.S. 
emergency departments conducted between 2006 and 2010. Patients whom primary 
reason for visiting the ED was chest pain were classified into two categories based 
on the physicians’ final diagnosis upon discharge: 1) well-defined diagnosis and 
2) ill-defined diagnosis(unspecific chest pain(ICD9= 786.5X)). Differences between 
groups in resource utilization which includes the number of procedures, diagnos-
tics and length of visits were examined using bivariate analyses. Results: There 
were 8,662 ER visits, representing more than 33 million ER visits between 2006 and 
2010 where the chief complaint was chest pain. More than half of those patients 
(54%) had an ill-defined diagnosis upon discharge. No difference between the two 
groups were detected in gender (female = 53%), race (72.8% white, 23.6% black and 
3.6% others), education, subsequent hospital admission (30%) and number of pro-
cedures (mean= 0.7, STD= 0.03). Patients with ill-defined diagnosis, however, were 
more likely to be admitted to observation units (5.8% vs. 1.9%, p< 0.001), received 
more blood tests (p< 0.001), diagnostics (p< 0.001), imaging procedures (44.1% vs. 
33.6%, p< 0.001) specifically X-ray (41.8% vs. 31.5%, p< 0.001) and also had higher 
length of visits (269.5 minutes vs. 241.6 minutes, p< 0.001). cOnclusiOns: The 
uncertainty dictated by the nature of chest pain symptom and the wide array of its 
underlying conditions inflict higher burden on the U.S. healthcare system. Better 
diagnostic techniques with higher sensitivity and specificity are badly needed to 
alleviate this issue.
observed claim were excluded. Cumulative rates were estimated for all HF-related 
hospitalizations, cardiovascular (CV) hospitalizations and all-cause hospitalizations, 
within the study period. Results were further categorized by types of insurance, spe-
cifically, commercial and Medicare advantage. Results: A total of 85,938 patients 
met the study criteria of which 68.3% (n= 58,732) had Medicare advantage coverage 
and 31.7% (n= 27,206) had commercial insurance. The mean age was 63 years for 
patients with commercial insurance and 77 for those with Medicare advantage. 
For the total population (commercial + Medicare advantage), the cumulative hos-
pitalization rate, inclusive of the first hospitalization, was 1.07 per patient-year for 
HF-related hospitalizations, 1.16 for CV-related hospitalizations (inclusive of HF) 
and 1.76 for all-cause hospitalizations. Cumulative hospitalization rates for patients 
with commercial insurance were 0.93, 1.00 and 1.52 for HF-related, CV, and all-cause 
hospitalizations, respectively. For patients with Medicare advantage coverage, the 
cumulative hospitalization rates were 1.14, 1.24 and 1.88 for HF-related, CV, and 
all-cause hospitalizations, respectively. cOnclusiOns: Patients with heart failure 
who have been hospitalized have frequent subsequent hospitalizations. On average, 
these individuals were hospitalized at least once a year for worsening heart failure, 
irrespective of their coverage.
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Objectives: To assess health care resource utilization and costs among U.S. 
patients diagnosed with cardiovascular disease (CVD) using the Veterans Health 
Administration (VHA) dataset. MethOds: Patients diagnosed with CVD or who 
underwent CVD-related procedures were identified (International Classification 
of Disease, 9th Revision, Clinical Modification [ICD-9-CM] diagnosis codes 410, 412, 
411.1, 411.81, 411.89, 434, 436, 437.0, 437.1, 438, 997.02, 435 and 428, ICD-9 procedure 
codes 00.66, 36.09 and current procedural terminology [CPT]-4 codes 33503-33545) 
using the VHA dataset from 01OCT2008 through 30SEPT2012. The initial diagnosis 
date was designated as the index date. Patients without a CVD diagnosis, who were 
of the same age, race and gender as study CVD patients, were identified for com-
parison. An index date was selected at random to minimize bias. Patients in both 
groups were required to be age ≥ 18 years with continuous medical and pharmacy 
benefits 1 year pre- and post-index date. One-to-one propensity score matching 
(PSM) was used to compare health care resource utilization and costs between the 
CVD and comparison groups during the follow-up period, adjusting for baseline 
demographic and clinical characteristics. Results: After risk-adjusted analysis 
using PSM, 536,125 patients in each group were matched. More CVD patients had 
inpatient admissions (14.40% vs. 1.43%, p< 0.0001) and emergency room (14.89% 
vs. 3.66%, p< 0.0001), outpatient office (60.90% vs. 47.19%, p< 0.0001), outpatient 
(61.35% vs. 47.99%, p< 0.0001) and pharmacy visits (64.41% vs. 54.89%, p< 0.0001) 
compared to those without CVD. CVD patients also incurred higher costs. Costs 
were significantly higher for CVD patients than for those without CVD ($8,248 
vs. $1,638, p< 0.0001). cOnclusiOns: CVD patients in the VHA population more 
frequently utilized health care resources and incurred higher costs than those 
without CVD.
PCV114
stuDy On tHe inPAtient HOsPitAl COsts Of HemOrrHAgiC strOke 
inPAtients in CHinA
Ma Y., Li Z., Wang L.
China Health Insurance Research Association, Beijing, China
Objectives: By estimating the direct medical cost of hemorrhagic stroke inpatients 
with urban basic health insurance scheme(exclude new rural cooperative medical care 
system )from 2010 to 2012 in China, we try to provide evidence for the government to 
manage the illness more effectively. MethOds: The inpatients with discharge diag-
nosis disease coded with ICD-10 (I60,I61,I62) were extracted from the China Health 
Insurance Research Association claim database which includes a nationwide, cross-
sectional sampling of inpatients from 2010 to 2012.In this paper, the descriptive statis-
tical analysis was used. Results: The analysis included 6715 patients(male:63.49%), 
patients with older than 50 years accounted for 82.87%(n= 5565). From 2010 to 2012, 
the average hospitalization expenses of each visits were 24656.0,23131.4 and 24995.0 
yuan(the average hospitalization expenses in the whole country:8849,8852and 9732 
yuan).Third-level hospitals, second-level hospitals and under second-level hospitals 
accounted for 57.85%,34.22% and 9.41%, respectively; total hospitalization expenses 
accounted for 71.35%, 22.69% and 5.85%; the average hospitalization expenses were 
30303.49, 16446.19 and 18624.96 yuan.78.78% of inpatient hospital expenses were 
occupied by patients who were over 50 years old. Reimbursement by urban basic 
health insurance scheme in 2010, 2011 and 2012 was 66.47%, 70.59% and 65.08%, 
respectively; while the corresponding patient co-pay burden was 33.53%, 29.41% and 
34.92%. cOnclusiOns: The average hospitalization expenses of each visits of hem-
orrhagic stroke was greater than the national average inpatients costs, although the 
reimbursement by urban basic health insurance scheme had increase dramatically, 
but the out-of-pocket spending was still high, especially for the poor.60% of inpatients 
went to third-level hospital, needing to establish patient grading care system at once, 
going back to community hospitals after recovery, which may reduce the burden of 
medical institutions and patients .
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